A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs ALT 801 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jul 2016 Status changed from active, no longer recruiting to discontinued.
    • 08 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top